NCT03529422 2025-07-20
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
UNC Lineberger Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University